"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

Among patients with heart failure with preserved ejection fraction (HFpEF), lower versus higher ranges of EF signal fundamentally different morphologies and hemodynamic responses, which may have ...

(UPDATED) Full results of the EMPEROR-Preserved trial affirm that empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) lowers the risk of CV death/hospitalization for heart failure in patients ...

Sacubitril/valsartan (Entresto) became the first drug to get a broad heart failure indication that reaches into the normal ejection fraction range for prevention of cardiovascular death and ...

Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Today we'll take a ...

Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...

Heart failure with preserved ejection fraction (HFpEF) has limited treatment options and remains a medical challenge. HFpEF is characterized by diastolic dysfunction with a normal ejection fraction.

Please provide your email address to receive an email when new articles are posted on . The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 12-1 that an expanded indication is warranted ...

Population-based studies report that the majority of elderly patients with heart failure have a normal ejection fraction (HF-NEF) and a history of hypertension. Left ventricular diastolic dysfunction, ...